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Studies of clinical series of psoriasis patients have
suggested an increased risk of nonmelanoma skin
cancer and melanoma; the risk of other neoplasms
has rarely been studied. In order to assess the incid-
ence of cancer in a nationwide series of psoriasis
patients from Sweden, we followed up, for the years
1965±89, 9773 patients with a hospital discharge diag-
nosis of psoriasis made during 1965±83, who were
alive and free from malignancy 1 y after ®rst dis-
charge. We compared their incidence of neoplasms
with that of the national population by computing
standardized incidence ratios (SIR). We observed a
total of 789 neoplasms [SIR 1.37, 95% con®dence
interval (CI) 1.28, 1.47]. There was an increase in the
risk of cancers of the oral cavity and pharynx (SIR
2.80, 95% CI 1.96, 3.87), liver (SIR 1.91, 95% CI
1.28, 2.74), pancreas (SIR 1.56, 95% CI 1.02, 2.23),
lung (SIR 2.13, 95% CI 1.71, 2.61), skin (squamous
cell carcinoma, SIR 2.46, 95% CI 1.82, 3.27), female
breast (SIR 1.27, 95% CI 1.00, 1.58), vulva (SIR 3.24,
95% CI 1.18, 7.06), penis (SIR 4.66, 95% CI 1.50,
10.9), bladder (SIR 1.43, 95% CI 1.03, 1.92), and
kidney (SIR 1.56, 95% CI 1.04, 2.25). The risk of
malignant melanoma was decreased (SIR 0.32, 95%
CI 0.10, 0.74). Despite some limitations (possible
diagnostic misclassi®cation, lack of data on treat-
ment, relatively short follow-up), our study provides
evidence against an increased risk of melanoma
among patients hospitalized for psoriasis. In addition
to nonmelanoma skin and genital cancers, patients
hospitalized for psoriasis were at increased risk of
several malignancies, in particular those associated
with alcohol drinking and tobacco smoking. Key
words: alcohol drinking/epidemiology/malignant mela-
noma/psoriasis/skin neoplasms. J Invest Dermatol
117:1531±1537, 2001
P
soriasis is a chronic proliferative disease of the skin, with
a variable and unpredictable clinical course characterized
by exacerbations and remissions. The morphology is
highly diverse, but the elemental lesion is an erythema-
tous and squamous lesion characterized by in¯ammation
and hypertrophy of the epithelium (Kerkhof, 1999). The etiology is
unknown; a genetic component has been demonstrated, which
might involve speci®c HLA haplotypes and possibly genes
encoding for cytokines such as interleukin enhancer binding factor
and tumor necrosis factor a. Environmental exposures have been
proposed as cofactors for psoriasis development: the evidence is
strong for streptococcal infection in the case of childhood psoriasis,
whereas data on tobacco smoking, alcohol drinking, diet, and use
of medicaments such as b-blockers and corticosteroids are
inconsistent. Psychogenic stress is likely to play a role in the
exacerbation of the disease, but the evidence of an etiologic role is
inadequate. Exposure to solar radiation reduces the lesions in a large
proportion of patients, but a role in primary prevention is not
demonstrated (Kerkhof, 1999).
Several agents used in psoriasis treatment are known or suspected
carcinogens. Exposure to X-rays is a cause of cancer at many sites
(IARC, 2000b). Nonmelanoma skin cancer, including genital
cancer, is caused by exposure to arsenic, coal-tar, and psoralen plus
ultraviolet-A (PUVA) (IARC, 1987). Ingestion or inhalation of
arsenic and inhalation of coal-tar fumes also cause cancers in other
organs (e.g., lung, kidney, urinary bladder); it is unclear whether
these effects are also present following dermal exposure. Exposure
to UVA and UVB probably increases the risk of nonmelanoma skin
cancer (IARC, 1992). Cyclosporin A and possibly methotrexate
might also increase the risk of skin cancer (IARC, 1987; Arellano,
1997). A carcinogenic effect of Grenz rays has been suggested,
although the risk is likely to be small if therapy recommendations
are followed (LindeloÈf, 1987). Some retinoid derivatives are
suspected teratogens (IARC, 1999).
Studies of series of psoriasis patients have suggested an increased
risk of nonmelanoma skin cancer and possibly of malignant
melanoma (see for example Stern et al, 1997a, 1998; Frentz and
Olsen, 1999; and see LindeloÈf, 1999, for review). An increased risk
of other neoplasms, such as cancers of the esophagus, lung, and
kidney, and non-Hodgkin's lymphoma, has sporadically been
reported in some of these investigations. The interpretation of the
evidence on cancer risk among psoriasis patients is complicated by
the small number of patients included in most series, precluding a
full evaluation of rare neoplasms. Furthermore, the selection of
patients in clinical series might result in the assessment of the effect
of special types of therapies used in subsets of patients.
Population-based series of patients may overcome these limita-
tions, as they tend to be large and to represent the experience of an
unselected series of patients. Given the lack of detailed information
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on clinical and pathologic aspects of the disease, however, they
cannot provide de®nite answers regarding pathologic pathways. To
our knowledge, three such population-based studies have been
reported, from Scotland (Alderson and Clarke, 1983), Denmark
(Olsen et al, 1992; Frentz and Olsen, 1999), and Finland
(Hannuksela-Svahn et al, 2000). The ®rst investigation, however,
was based on a small number of patients.
We report the results of the follow-up of a large cohort of
patients hospitalized for psoriasis in Sweden during 1965±83. We
speci®cally aimed at testing the hypothesis that psoriasis (or its
treatment) increases the risk of nonmelanoma skin cancer and of
malignant melanoma. In addition, we wanted to assess the risk of
other neoplasms in an unselected population of hospitalized
psoriasis patients, as well as their mortality pattern.
MATERIALS AND METHODS
Materials Since 1964, the Swedish National Board of Health and
Welfare has collected computerized information on individual hospital
discharges in the In-patient Register. The coverage of the population has
increased steadily: in 1969, the Register covered 60% of the population
of the country; by the end of 1983, the percentage was 85%. Each
record of the Register includes the unique personal identi®cation
number of the patient, the dates of admission and discharge, up to eight
discharge diagnoses, and data on hospital departments. The discharge
diagnoses were coded using the seventh revision of the International
Classi®cation of Diseases (ICD-7) (WHO, 1955) until 1968, and the
eighth revision (ICD-8) (WHO, 1965) thereafter.
We considered all records in the In-patient Register with a hospital
discharge diagnosis of psoriasis (ICD-7 code 706; ICD-8 code 696)
during the period 1965±83, and identi®ed 14,421 such records. We
linked this cohort to the nationwide Registers of Total Population,
Cause of Death, and Population Migration to identify all patients who
lived in Sweden during the study period (1965±89). This resulted in the
exclusion of 1466 records with incomplete or incorrect registration
numbers that did not correspond to any person. We also obtained the
date and cause of death for the deceased patients or the date of
emigration for those who emigrated. This linkage resulted in the
exclusion of 211 patients who had died during the index admission. The
causes of death were coded according to ICD-8 (WHO, 1965) until
1986 and according to the ninth revision (ICD-9) (WHO, 1975)
thereafter. We ®nally linked the cohort to the Swedish Cancer Register,
founded in 1958 and estimated to be 98% complete, including squamous
cell carcinoma of the skin (Mattsson, 1977; Mattsson and Wallgren,
1984). The linkage with the Swedish Cancer Register covered again the
period 1965±89 and aimed at identifying all cases of cancer that occurred
among the cohort of psoriasis patients, either before (prevalent cases) or
after (incidence cases) the ®rst hospital discharge with a diagnosis of
psoriasis. Although we did not assess the completeness and reliability of
the linkage between the In-patient Register and the Swedish Cancer
Register, a similar exercise conducted on the linkage between the
Cancer Register and the 1960 Census revealed a completeness of 98.8%
and a reliability of 99.5% (Wiklund and Eklund, 1986). We excluded at
this stage 547 patients with a prevalent cancer. A further 241 patients
were excluded at various steps of the linkage procedures because of
inconsistencies between the dates used for the linkage. Finally, we
restricted the cohort to patients with a diagnosis coded as 706.00 or
706.09 in ICD-7, or as 696.1 in ICD-8, thus excluding 1655 patients
with psoriasis-related conditions such as parapsoriasis.
We excluded the ®rst year of observation following the index
admission in order to reduce selection bias, which could occur if psoriasis
patients who develop a cancer or die within 1 y are more likely to be
hospitalized than other psoriasis patients, as well as detection bias, which
could occur if a cancer is diagnosed during the diagnostic and therapeutic
procedures involved in the management of psoriasis. This resulted in the
exclusion of 528 patients who developed a cancer, died, or emigrated
within 1 y of the index admission. The ®nal cohort of psoriasis patients,
with valid data, who were alive and free from cancer 1 y after index
admission, comprised 9773 individuals.
Methods The observed cancer cases in our analysis represent ®rst
cancers diagnosed in the cohort members. They were obtained from the
Swedish Cancer Register, which codes malignant neoplasms according to
the ICD-7 classi®cation (WHO, 1955). Basal cell carcinomas of the skin
are not recorded in the Cancer Register. We calculated the expected
number of cancer cases by multiplying the gender-, 5-y-age-group- and
calendar-year-speci®c incidence rates by the person-year distribution of
the cohort. The rates used in the calculation were derived from the
entire Swedish population, after excluding cancer cases ®rst detected at
autopsy.
All analyses are based on the standardized incidence ratio (SIR),
de®ned as the ratio of the observed to the expected cases of cancer. We
calculated the 95% con®dence interval (CI) for each SIR on the
assumption of a Poisson distribution of the number of observed cases.
Similarly, we calculated standardized mortality ratios (SMR) and their
95% CI, using national mortality rates to calculate the expected numbers
of deaths.
In separate analyses, person-years of observation were divided accord-
ing to time elapsed since the index visit. No information was available
on the severity or duration of psoriasis, nor on the treatment provided.
The information available on other discharge diagnoses at the time of the
index admission, however, allowed us to stratify the cohort by whether
psoriasis was the only, the primary, or a secondary diagnosis, and by year
of index hospitalization. Similarly, the information available on other
diseases at the index or subsequent admissions enabled us to separate
those psoriasis patients who also suffered from diseases that are possibly
associated with psoriasis and that would also increase the risk of cancer
such as alcoholism and liver cirrhosis.
RESULTS
Table I provides summary information on the cohort used in the
study. The patients in the cohort provided 93,776 person-years of
observation (mean duration of follow-up, 10.6 y). Men comprised
54.3% of the cohort and contributed 52.4% of total person-years:
they experienced on average a shorter follow-up (10.3 y) than
women (11.0 y). The mean year of index admission was 1976 and
the mean age at index hospitalization was 50.1; 25% of patients
were 35 or younger and another 25% were over 65. There were
3004 patients with age at index hospitalization below 40: they
contributed 37,125 person-years of observation.
The number of observed cases of cancer was signi®cantly in
excess of the expected number, resulting in an overall SIR of 1.37
(95% CI 1.28, 1.47). The excess risk was present in both genders.
The analysis by speci®c neoplasm revealed a complex picture
(Table II). A strong excess of mycosis fungoides was observed in
men, based on ®ve cases, but not in women. The risk of cancers of
the oral cavity and pharynx, esophagus, liver, pancreas, lung, skin
(squamous cell carcinoma), bladder, and kidney was signi®cantly
increased. A signi®cant increase in risk was found in women for
breast cancer and in men for cancer of the genital organs other than
the prostate. Finally, an increased risk (SIR > 1.5), which did not
reach statistical signi®cance, was found for cancer of the female
genital organs other than the uterus and ovary, and for
nonlymphocytic leukemia. Skin melanoma was the only neoplasm
for which a decreased risk was observed.
The six cases of cancer of the female genital tract were all vulvar
cancers (SIR 3.24, 95% CI 1.18, 7.06). The eight cases of cancers of
Table I. Distribution of patients hospitalized for psoriasis
and person-years by gender and selected characteristics
Characteristic Patients Person-years
Total 9,773 93,775.6
Gender
Men 5,306 49,138.3
Women 4,467 44,637.2
Duration of follow-up
1±4 y 1,234a 27,351.4
5±9 y 2,926a 36,475.9
10±14 y 2,839a 20,646.3
15+ y 2,774 9,302.0
Presence of other diagnoses
Psoriasis as only diagnosis 5,164 55,512.7
Other diagnoses, psoriasis as primary 1,652 14,755.0
Other diagnoses, psoriasis as secondary 2,957 23,507.9
aNumber of patients contributing up to each category.
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the male genital tract consisted of three cases of testicular cancer
(SIR 1.67, 95% CI 0.33, 4.87) and ®ve cases of penile cancer (SIR
4.66, 95% CI 1.50, 10.9). None of the cases was registered as scrotal
cancer (0.04 cases expected).
Most kidney cancers were renal cell carcinomas (22 cases, SIR
1.48, 95% CI 0.92, 2.23). There was a nonsigni®cant increase in
the incidence of cancer of the renal pelvis (three cases, SIR 1.59,
95% CI 0.32, 4.65). The SIR of primary liver cancer was 3.19 (95%
CI 1.86, 5.11), and that of gallbladder cancer was 0.96 (95% CI
0.35, 2.09).
An increased risk of squamous cell carcinoma of the skin was
present in all major anatomical regions (trunk: seven cases, SIR
5.12, 95% CI 2.05, 10.5; upper limbs: ®ve cases, SIR 2.55, 95% CI
0.82, 5.94; lower limbs: 13 cases, SIR 9.15, 95% CI 4.87, 15.7),
except for the head and neck (17 cases, SIR 1.33, 95% CI 0.77,
2.13).
The risk of cancer did not vary systematically according to time
since index hospitalization: the SIR was 1.42 (95% CI 1.24, 1.61) at
1±4 y, 1.36 (1.21, 1.53) at 5±9 y, 1.33 (1.14, 1.55) at 10±14 y, and
1.36 (1.08, 1.68) at 15 y or more of follow-up. The SIR of mycosis
fungoides was 37.9 (three cases) at 1±4 y and 20.3 (two cases) at 5±
9 y of follow-up, whereas no cases occurred after 10 y or more
(0.08 expected). In addition to mycosis fungoides, we conducted
the analysis by time since index admission for those neoplasms with
a signi®cant increased risk and at least 20 observed cases (Fig 1). In
the case of cancer of the oral cavity/pharynx, pancreas, or skin
(squamous cell carcinoma), we found that the risk increased with
duration of follow-up: the p-values of the test for linear trend of the
SMR were 0.08, 0.23, and 0.03, respectively. No trend with
duration of follow-up was apparent for cancers of the liver, lung,
and breast. The increase in risk of kidney cancer was restricted to
the ®rst period of follow-up and that of bladder cancer to the
second period. The analysis on risk of melanoma by time of index
hospitalization was hampered by the small number of cases: a
decreased risk, however, was suggested throughout the entire
follow-up.
The analysis of patients with age at hospitalization below 40
provided results consistent with those of the overall cohort: these
patients experienced 54 cancers (SIR 1.44, 95% CI 1.08, 1.88) and
had an increased incidence of squamous cell carcinoma of the skin
(eight cases, SIR 15.8, 95% CI 6.82, 31.2) but not of malignant
melanoma (two cases, SIR 0.59, 95% CI 0.07, 2.12).
For more than half of the patients included in the study, psoriasis
was the only discharge diagnosis at index admission. The risk of
cancer in this group was similar (SIR 1.31, 95% CI 1.18, 1.45) to
that of patients with several discharge diagnoses including psoriasis
as the primary diagnosis (SIR 1.34, 95% CI 1.13, 1.57, p-value of
difference 0.9), but lower than that of patients with psoriasis as a
secondary diagnosis (SIR 1.49, 95% CI 1.32, 1.68, p-value 0.11).
The main primary diagnoses associated with a secondary diagnosis
of psoriasis concerned erysipelas (3.9%), eczema (4.3%), other skin
diseases (7.8%), rheumatoid arthritis (7.1%), other rheumatic and
arthritic diseases (6.7%), in addition to highly prevalent diseases
such as diabetes and ischaemic heart disease. The excess of liver
cancer was present only among patients with a disease other than
psoriasis as primary diagnosis (SIR 2.60, 95% CI 1.38, 4.44). In the
case of cancers of the rectum, pancreas, and male genital organs,
however, the SIR was highest among patients with psoriasis as the
only diagnosis (rectum 1.37, 95% CI 0.81, 2.16; pancreas 1.75, 95%
CI 0.98, 2.88; male genital organs 3.40, 95% CI 1.24, 7.39).
Table II. Standardized incidence ratio of selected neoplasms among patients hospitalized for psoriasisa
Men Women Both genders
N SIR 95% CI N SIR 95% CI N SIR 95% CI
All cancers 444 1.34 1.22,1.47 345 1.41 1.27, 1.57 789 1.37 1.28-1.47
Oral cavity, pharynx 25 2.60 1.68, 3.84 11 3.37 1.68, 6.04 36 2.80 1.96, 3.87
Oesophagus 13 3.00 1.59, 5.13 4 3.03 0.82, 7.76 17 3.01 1.75, 4.81
Stomach 22 1.07 0.67, 1.62 10 0.99 0.47, 1.82 32 1.04 0.71, 1.47
Colon 26 1.08 0.71, 1.59 26 1.25 0.81, 1.83 52 1.16 0.87, 1.52
Rectum 19 1.10 0.66, 1.71 17 1.62 0.94, 2.60 36 1.29 0.91, 1.79
Liver 18 2.52 1.49, 3.98 11 1.36 0.68, 2.44 29 1.91 1.28, 2.74
Pancreas 14 1.34 0.73, 2.24 14 1.82 0.99, 3.05 28 1.56 1.02, 2.23
Larynx 6 1.55 0.57, 3.37 0 [0.32] 0, 11.5 6 1.43 0.52, 3.12
Lung 65 1.91 1.48, 2.44 25 3.00 1.94, 4.43 90 2.13 1.71, 2.61
Connective tissue 1 0.47 0.01,2.59 3 1.99 0.40, 5.81 4 1.09 0.29, 2.80
Melanoma 3 0.34 0.07, 1.00 2 0.29 0.03, 1.05 5 0.32 0.10, 0.74
SCC of the skin 35 2.75 1.92, 3.83 13 1.92 1.02, 3.28 48 2.46 1.82, 3.27
Breast 1 1.89 0.02, 10.5 78 1.27 1.00, 1.58 79 1.27 1.01, 1.58
Cervix ± ± ± 11 1.44 0.72, 2.57 11 1.44 0.72, 2.57
Endometrium ± ± ± 15 1.11 0.62, 1.84 15 1.11 0.62, 1.84
Ovary ± ± ± 19 1.38 0.83, 2.16 19 1.38 0.83, 2.16
Female genital organs ± ± ± 6 2.47 0.90, 5.37 6 2.47 0.90, 5.37
Prostate 77 0.96 0.76, 1.21 ± ± ± 77 0.96 0.76, 1.21
Male genital organs 8 2.69 1.16, 5.30 ± ± ± 8 2.69 1.16, 5.30
Bladder 33 1.37 0.95, 1.93 10 1.62 0.78, 2.98 43 1.43 1.03, 1.92
Kidney, pelvis 13 1.10 0.58, 1.88 15 2.45 1.37, 4.04 28 1.56 1.04, 2.25
Brain 4 0.49 0.13, 1.25 6 0.92 0.34, 2.00 10 0.68 0.33, 1.25
Thyroid 4 2.62 0.71, 6.71 3 1.00 0.20, 2.92 7 1.55 0.62, 3.19
Hodgkin's disease 1 0.58 0.01, 3.24 0 [1.04] 0, 3.53 1 0.36 0.01, 2.02
Non-Hodgkin's lymphomab 15 1.56 0.87, 2.57 7 1.19 0.48, 2.45 22 1.42 0.89, 2.15
Mycosis fungoides 5 26.7 8.60, 62.3 0 [0.07] 0, 51.3 5 19.3 6.22, 45.1
Multiple myeloma 5 0.92 0.30, 2.14 6 1.70 0.62, 3.69 11 1.22 0.61, 2.19
Lymphocytic leukaemia 2 0.44 0.05, 1.58 4 1.89 0.51, 4.84 6 0.90 0.33, 1.96
Non-lymphocytic leukaemia 6 1.74 0.64, 3.79 5 2.18 0.70, 5.09 11 1.92 0.96, 3.43
aN, number of observed cases; SIR, standardized incidence ratio; Cl, con®dence interval; SCC, squamous cell carcinoma. When no cases were observed, expected cases
are reported in square brackets.
bExcluding mycosis fungoides.
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Despite some ¯uctuation that might be attributed to chance, the
results for the remaining neoplasms resulted in similar SIR in the
three groups of patients with psoriasis as the only, the primary, or a
secondary diagnosis (data not shown in detail).
For most neoplasms, there was no difference in the SIR
according to whether the index hospitalization occurred before or
after 1 January 1976. The only exceptions were kidney cancer, for
which the SIR was only elevated during the ®rst period (SIR 2.03,
95% CI 1.26, 3.10), and non-Hodgkin's lymphoma, which showed
an opposite pattern (SIR for second period 1.96, 95% CI 1.07,
3.29). The increased incidence of alcohol-related diseases persisted
when we excluded patients who also had a hospital discharge
diagnosis for alcoholism or liver cirrhosis. In particular, the SIR of
oral and pharyngeal cancer was 2.04 (95% CI 1.30±3.03), and that
of primary liver cancer was 1.74 (95% CI 1.12±2.56).
The analysis of the mortality experience of patients hospitalized
for psoriasis resulted in an overall SMR of 1.94 (95% CI 1.88, 2.00)
(Table III). Among the non-neoplastic causes of death, the SMR
was increased for infectious diseases, respiratory diseases (in
particular pneumonia and chronic obstructive pulmonary disease),
cardiovascular diseases (and all the major nosologic entities of this
group), neurologic and psychiatric diseases, diabetes, digestive
diseases (in particular liver cirrhosis), genitourinary diseases,
muscoloskeletal diseases, and external causes (in particular wounds,
intoxications, and internal and brain traumas). A strong increase was
found in the SMR of non-neoplastic skin diseases. Restriction of
the mortality analysis to patients with psoriasis as the only cause of
hospitalization con®rmed the increased mortality from respiratory
diseases, cardiovascular diseases, mental disorders, liver cirrhosis,
and external causes, although most increases in the SMR were less
pronounced than in the analysis of the entire cohort.
DISCUSSION
This large, population-based study of cancer occurrence among
Swedish patients hospitalized for psoriasis provides no evidence for
an increased risk of melanoma. In addition to squamous cell
carcinoma of the skin, these patients were at increased risk of
several malignancies, in particular those associated with alcohol
drinking and tobacco smoking. It is important to stress, however,
that these results are not directly applicable to all psoriasis patients,
the majority of whom are not hospitalized because of their disease.
Two factors complicate the comparison of our results with
previous investigations. The ®rst problem is that most published
studies are based on groups of psoriasis patients treated in one or
several specialized centers. Although these studies contain import-
Figure 1. Risk of selected neoplasms among
patients hospitalized for psoriasis by duration
of follow-up.
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ant information on the clinical aspects of the disease and on its
treatment, they are likely to re¯ect the experience of a selected
group of patients whose cancer experience might be biased
compared to the overall population of patients. Three investigations
included a population-based series of psoriasis in-patients: they are
from Scotland (Alderson and Clarke, 1983), Denmark (Olsen et al,
1992; Frentz and Olsen, 1999), and Finland (Hannuksela-Svahn
et al, 2000). The second problem is the possibility of publication
bias. Given the small size of most previous studies, it is possible that
results that did not reach the signi®cance level of 5% were not
reported.
Two cohorts of Swedish psoriasis patients that partially overlap
with our study population have been studied with respect to cancer
risk: LindeloÈf and colleagues (LindeloÈf et al, 1990) studied over
20,000 members of the Swedish Psoriasis Association and found an
excess of male breast cancer and of female kidney cancer. The same
authors studied a group of nearly 5000 patients treated during
1974±85 with PUVA, 64% of whom for psoriasis, and reported an
increased risk of respiratory cancer in both genders and of kidney
cancer in women (LindeloÈf et al, 1991, 1999). In addition,
Lindegard (1986) studied 372 cases of psoriasis diagnosed during
1970±79 among the residents of Gothenburg and found an
association with lung cancer in women born after 1922. The
overlap of these populations with our cohort is unclear. It is likely,
however, that the patients included in our study represent more
severe cases, as they were all hospitalized and, for about 70% of
them, psoriasis was the only or main discharge diagnosis.
Several biases might have operated in our study. Psoriasis
patients, in particular those who underwent hospitalization, may
have been subject to increased clinical surveillance, resulting in
higher detection and diagnosis of neoplasms, compared to the
national population. This is plausible in particular for skin
neoplasms, and it may have accounted for at least part of the
excess of squamous cell carcinoma of the skin, including cancer of
the external genitals. It is less plausible, however, that this bias is
implicated in the increase in occurrence of cancers of other organs,
in particular those with a severe clinical course.
A second possible bias concerns diagnostic misclassi®cation
between psoriasis and other dermatologic conditions. An erroneous
diagnosis of psoriasis would result, on the one hand, in a false
positive association if the misclassi®ed condition were either a
neoplasm (or a preneoplastic lesion) itself or a disease causally
associated with cancer. Misdiagnosis of psoriasis as a disorder not
associated with increased cancer risk, on the other hand, would
reduce the strength of any association between psoriasis and cancer.
The very strong increase in risk of mycosis fungoides in men can
probably be explained by such bias. On the one hand, cases of this
skin lymphoma, in particular in the initial stages, can be diagnosed
as psoriasis (Elmer and George, 1999); on the other hand, large-
plaque parapsoriasis is a lesion closely related to mycosis fungoides
and, despite the fact that we excluded patients with a discharge
diagnosis coded as parapsoriasis, it is possible that misclassi®cation
with psoriasis occurred. Other diseases that can be misdiagnosed as
psoriasis, e.g., seborrhoeic dermatitis and other chronic dermatites,
are not known to be associated with mycosis fungoides, lymphoma,
or cancer. We did not validate the diagnoses obtained from the In-
patient Register.
Furthermore, the increased risk of all neoplasms might be due to
a bias arising from the linkage of records from different registers. In
a similar study of patients hospitalized for scleroderma, however,
those with systemic sclerosis had an increased incidence of cancer,
whereas the risk of cancer among patients with localized
scleroderma was not different from that of the general population,
arguing against such ``registration'' or ``linkage'' bias (Rosenthal et
al, 1995).
For neoplasms for which bias can be excluded, explanations for
the observed associations include a carcinogenic effect of treatment,
and a role of cancer risk factors also associated with psoriasis. Given
the known or suspected carcinogenicity of several agents used in
psoriasis control, the lack of information on the treatment
Table III. Standardized mortality ratios for selected non-neoplastic causes among patients hospitalized for psoriasisa
Whole cohort Psoriasis as only diagnosis
N SMR 95% CI N SMR 95% CI
All causes 3813 1.94 1.88, 2.00 1392 1.56 1.48, 1.64
Infective diseases 28 2.25 1.49, 3.25 8 1.41 0.61, 2.77
Malignant neoplasms 616 1.48 1.36, 1.60 252 1.30 1.15, 1.47
Respiratory diseases 290 2.16 1.91, 2.42 94 1.58 1.27, 1.93
Pneumonia 169 2.02 1.73, 2.35 61 1.66 1.27, 2.14
Bronchitis 35 2.06 1.43, 2.86 8 1.06 0.46, 2.09
Emphysema 29 3.13 2.09, 4,49 6 1.44 0.53, 3.13
Asthma 24 2.46 1.58, 3.67 6 1.31 0.48, 2.85
Cardiovascular dis. 2066 1.87 1.79, 1.95 715 1.45 1.35, 1.56
Isch. heart dis. 1357 1.97 1.87, 2.08 479 1.55 1.42, 1.70
Cerebrovasc. dis. 334 1.60 1.43, 1.78 123 1.33 1.11, 1.59
Arterial diseases 134 1.83 1.54, 2.17 43 1.34 0.97, 1.80
Diabetes mellitus 88 3.14 2.52, 3.87 24 1.88 1.20, 2.79
Neurological dis. 33 1.77 1.22, 2.49 12 1.35 0.69, 2.35
Mental disorders 66 2.91 2.25, 3.70 33 3.03 2.08, 4.25
Alcoholism 51 7.19 5.35, 9.44 25 6.37 4.12, 9.39
Digestive diseases 246 3.86 3.39, 4.37 98 3.31 2.69, 4.03
Liver cirrhosis 133 8.13 6.81, 9.64 50 6.05 4.49, 7.97
Genito-urinary dis. 74 2.54 2.00, 3.19 20 1.56 0.96, 2.42
Skin/subcut. dis. 20 17.7 10.8, 27.3 4 7.87 2.11, 20.1
Muscoloskeletal. dis. 27 3.34 2.20, 4.85 3 0.81 0.16, 2.35
External causes 213 2.29 2.00, 2.62 101 2.08 1.69, 2.53
Trauma to organs 21 7.13 4.42, 10.9 12 7.26 3.75, 12.7
Open wounds 66 2.19 1.69, 2.78 27 1.99 1.31, 2.89
Trauma of CNS 53 2.04 1.53, 2.67 28 1.91 1.27, 2.76
Adverse toxic eff. 39 3.81 2.71, 5.21 15 2.53 1.42, 4.18
aN, number of observed cases; SMR, standardized mortality ratio; Cl, con®dence interval; CNS, central nervous system.
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experienced by the individual patients in the cohort is a major
limitation of our study. Another important limitation is the lack of
information on type of psoriasis and on the age at onset of the
disease, including age at ®rst hospitalization (as index hospitalization
in our study might not correspond to ®rst hospitalization, in
particular among older patients).
The cohort of psoriasis patients experienced an increased risk of
several neoplasms, resulting in an overall increase in cancer risk.
Although each increase might have a different explanation (see
detailed discussion below), one unifying hypothesis might be found
in the increasing turnover of psoriatic cells, which might re¯ect a
general alteration in cell proliferation and cell cycle control
mechanisms. The increase in overall cancer incidence parallels the
results of a similar study of psoriasis patients from Denmark (Frentz
and Olsen, 1999) and might re¯ect, in addition to a systemic
carcinogenic effect of treatment, a general proneness of psoriasis
patients to carcinogenesis, possibly linked to increased cell prolif-
eration beyond the epidermis. In addition, statistically signi®cant
results can be generated when many comparisons are performed, as
in our study.
In particular, an increased risk of nonmelanoma skin cancer has
been reported in many series of psoriasis patients (Alderson and
Clarke, 1983; Stern et al, 1984, 1998; Tanew et al, 1986; Henseler
et al, 1987; Forman et al, 1989; LindeloÈf et al, 1991; Chuang et al,
1992; Hannuksela et al, 1996; McKennan et al, 1996; Frentz and
Olsen, 1999; Hannuksela-Svahn et al, 2000). The association is
attributed to the carcinogenic effect of PUVA (IARC, 1987). The
interpretation of the data is complicated, however, by the fact that
most patients treated with PUVA or similar regimens have also
been treated with other drugs, including known or suspected skin
carcinogens such as arsenic, coal-tar, cyclosporine A, and metho-
trexate. The available evidence is not consistent as to whether
PUVA alone increases the risk of nonmelanoma skin cancer, as
shown for example in a large prospective study from the U.S.A.
(Stern et al, 1984, 1998), or whether only patients with exposure to
skin carcinogens prior to treatment are at increased risk, as shown in
a similar study from Europe (Forman et al, 1989). A recent meta-
analysis, however, provided evidence of an increase in the
incidence of nonmelanoma skin cancer following high-dose
PUVA (Stern and Lunder, 1998). Among the other drugs used in
psoriasis treatment, methotrexate per se does not seem to increase
the risk of skin cancer (Stern et al, 1982; Nyfors and Jensen, 1983;
Hannuksela-Svahn et al, 2000), whereas an effect of cyclosporine
has been suggested (Arellano, 1997; Paquet and Pierard, 1998). If
the association between psoriasis treatment and increased incidence
of nonmelanoma skin cancer is well established, the magnitude of
the excess might be dif®cult to establish because of possible
surveillance bias (e.g., more complete reporting of cases of skin
cancer among psoriasis patients compared to the general popula-
tion).
Our result of a relative risk on the order of 2.5 for squamous cell
carcinoma of the skin is in agreement with that of the population-
based studies from Denmark and Finland (Olsen et al, 1992; Frentz
and Olsen, 1999; Hannuksela-Svahn et al, 2000), whereas studies of
selected groups of PUVA-treated patients resulted in higher risk
estimates: relative risks of 18 in the U.S.A. and 4±6 in Sweden
(Stern et al, 1998; LindeloÈf et al, 1999). The lack of excess of
nonmelanoma skin cancer in the cohort of members of the Swedish
Psoriasis Association (LindeloÈf et al, 1990) can be explained by the
milder form of the disease experienced by many of these members,
resulting in lower exposure to PUVA and other carcinogens.
Arsenic was used in Sweden until the 1960s for severe forms of the
disease and might be responsible for part of the excess. The excess
of squamous cell carcinoma of the skin was greatest on the trunk
and the lower limbs, as was also found in the study from Denmark
(Frentz and Olsen, 1999). In addition, we detected a large excess
risk of cancers of the penis and vulva, which would be worth
investigating in other populations of psoriasis patients.
We found a decreased risk of malignant melanoma, which is
unlikely to be due to artefact. Most previous studies reported no
increased risk of melanoma among psoriasis or PUVA-treated
patients (Elwood et al, 1986; Olsen et al, 1992; Hannuksela et al,
1996; Frentz and Olsen, 1999; Hannuksela-Svahn et al, 2000). One
notable exception is the latest follow-up of the multicenter cohort
of American psoriasis patients treated with PUVA, which revealed
an increased risk after 15 y of follow-up (Gupta et al, 1988; Stern
et al, 1997a). In our study, no excess was found even 15 y or more
after ®rst hospital discharge (one observed and 2.2 expected cases).
Although it is established that solar radiation increases the risk of
malignant melanoma, intermittent exposure seems to play a bigger
role than cumulative exposure (IARC, 1992; Armstrong and
English, 1996). The evidence that exposure to arti®cial UV light
increases the risk of melanoma is not conclusive (IARC, 1992).
Our study offers no support to the hypothesis that PUVA (or other
treatment for psoriasis), as experienced by patients hospitalized for
this condition in Sweden, increases the risk of melanoma after a
long latency period. Possible explanations of the apparent discrep-
ancy of results on melanoma in studies of psoriasis patients from the
U.S.A. and Northern Europe are as follows: (i) a role of
background melanoma rate, which in men is higher in the
U.S.A. than in Denmark, Finland, or Sweden; (ii) differences in
frequency and modality of PUVA treatment; (iii) occurrence of
psoriasis-linked melanoma before ®rst hospitalization for psoriasis
itself. The lack of an increase in risk of melanoma among patients
with index hospitalization before age 40, however, speaks against
the hypothesis of an elevated incidence of this neoplasm before
hospitalization for psoriasis.
Apart from mycosis fungoides, the overall risk of non-Hodgkin's
lymphoma was not increased in our cohort. There was an increased
risk among patients with the ®rst visit after 1975, however, which
might re¯ect the effect of immunosuppressive drugs used in recent
decades for the management of psoriasis. An increased risk of non-
Hodgkin's lymphoma has been reported in cohorts of Finnish
patients (Hannuksela et al, 1996; Hannuksela-Svahn et al, 2000), as
well as in groups of psoriasis patients treated with cyclosporine A
(Arellano, 1997). Further surveillance of the risk of lymphoma in
our cohort is warranted.
We have detected an increased risk of breast cancer among the
patients in our study. Although the magnitude of the excess is
modest, it is consistently found throughout the follow-up. A similar
modest increase in risk has been reported among PUVA-treated
patients from the U.S.A. (Stern et al, 1997b), but not among
psoriasis patients from Denmark or Finland (Frentz and Olsen,
1999; Hannuksela-Svahn et al, 2000). In a previous study of
Swedish members of the Psoriasis Association, breast cancer risk
was increased among men but not among women. Stern et al
(1997b) evoked surveillance bias as a possible explanation for their
®ndings (in their study, the excess risk was strongest in the ®rst
period of follow-up). This is not a likely explanation for our
®ndings, as the risk is elevated 15 y or more after the ®rst visit for
psoriasis. In the American study, PUVA dose was not associated
with breast cancer risk (Stern et al, 1997b). Other carcinogens used
in the past for psoriasis treatment, like arsenic and tar, are not
known to be active on the breast. A possible explanation of our
®ndings is the therapeutic use of X-rays and radium (IARC,
2000b).
In addition to agents used for psoriasis treatment, lifestyle
factors ± in particular alcohol drinking and tobacco smoking ±
might have acted as confounders in our study. There is evidence of
an increased risk of psoriasis among heavy smokers and drinkers
(Kvali et al, 1985; Monk and Neil, 1986; Poikolainen et al, 1990;
Naldi et al, 1992). In a survey from Gothenburg, there was an
increased prevalence of alcoholism and liver cirrhosis, but not of
chronic respiratory diseases, among psoriasis patients compared to
the general population (Lindegard, 1986). Our cohort experienced
a large increase in the risk of neoplasms known to be associated
with alcohol drinking and tobacco smoking [cancers of the oral
cavity, esophagus, liver, pancreas, lung, kidney (tobacco only), and
breast (alcohol only)]. We have no information on the smoking and
drinking habits of the patients in our study. The analysis of non-
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neoplastic causes of death (Table III), however, reinforces the
suspicion that alcohol drinking and tobacco smoking were highly
prevalent among the patients included in our study.
The systematic analysis of mortality represents an original aspect
of our investigation. The striking increase in mortality above
expectation based on national mortality ®gures can be attributed, at
least in part, to increased exposure to alcohol and tobacco. It is
likely, however, that aggressive treatment given for psoriasis
increased the risk of dying from chronic diseases other than cancer,
such as cardiovascular diseases.
Despite several important limitations (possible diagnostic mis-
classi®cation, lack of data on treatment, relatively short follow-up,
possible false positive results resulting from multiple comparisons),
our study has provided no evidence for an increased risk of
melanoma among patients hospitalized for psoriasis. Our study has
not con®rmed previous reports of an increase in non-Hodgkin's
lymphomas other than mycosis fungoides. Furthermore, our study
has provided indirect (albeit strong) evidence that consumption of
alcohol and tobacco is increased among patients with severe
psoriasis. Future studies on cancer risk among psoriasis patients
should include the strengths of this investigation (large study
population, completed follow-up, population-based dimension),
together with detailed and valid information on the clinical aspects
of the disease, the treatment experienced by these patients, and
their lifestyle habits.
We wish to thank J.F. Fraumeni, Jr., for his comments on an earlier version of the
manuscript.
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